Synephrine API Manufacturers & Suppliers
0 verified results
Commercial-scale Suppliers
Join our notification list by following this page.
Click the button below to find out more
Click the button below to switch over to the contract services area of Pharmaoffer.






Synephrine | CAS No: 94-07-5 | GMP-certified suppliers
A medication that acts as an adrenergic agonist used in cardiovascular and respiratory therapies for vasoconstriction and decongestion, requiring precise isomeric purity for pharmaceutical use.
Therapeutic categories
Product Snapshot
- Synephrine is typically formulated as an oral small molecule ingredient
- It is primarily investigated for use in weight management and metabolic enhancement applications
- Synephrine currently holds an experimental status with no established regulatory approvals from key agencies
Clinical Overview
Synephrine is categorized pharmacologically within adrenergic agents and functions as an adrenergic agonist, particularly engaging alpha-adrenergic receptors. Its classification spans several drug categories including adrenergic alpha-agonists, sympathomimetics, and vasoconstrictor agents. The compound is recognized for its longer-acting adrenergic effects relative to endogenous catecholamines like norepinephrine, influencing cardiovascular parameters such as heart rate and vascular tone, with associated agents producing tachycardia and hypertension.
Despite its broad functional classification, specific clinical indications and detailed mechanism of action for synephrine remain unspecified, and its current regulatory status is experimental. Synephrine’s pharmacokinetic and ADME parameters are not well characterized in the literature, limiting comprehensive assessment of absorption, distribution, metabolism, and excretion in humans.
Safety considerations focus primarily on its adrenergic stimulation, which may contribute to cardiovascular risks such as hypertension and tachyarrhythmias. Regulatory scrutiny tends to emphasize these potential adverse effects, particularly in formulations intended for systemic use.
In terms of sourcing and quality, procurement of synephrine API requires stringent analytical verification to distinguish it from phenylephrine and other structurally related analogs. Purity, isomeric composition, and compliance with pharmacopeial standards are critical quality attributes to ensure consistency and safety in downstream pharmaceutical applications.
Identification & chemistry
| Generic name | Synephrine |
|---|---|
| Molecule type | Small molecule |
| CAS | 94-07-5 |
| UNII | PEG5DP7434 |
| DrugBank ID | DB09203 |
Pharmacology
Targets
| Target | Organism | Actions |
|---|---|---|
| Alpha-1 adrenergic receptors | Humans |
Formulation & handling
- Synephrine is a small molecule phenolic compound suitable for oral formulation due to its solid state and moderate water solubility.
- Its low LogP value suggests limited lipophilicity, impacting formulation strategies for bioavailability optimization.
- Stability and handling considerations should focus on protecting the compound from oxidation given its phenolic functional group.
Regulatory status
Synephrine is a type of Adrenergic agents
Adrenergic agents are a subcategory of pharmaceutical active pharmaceutical ingredients (APIs) that target the adrenergic system in the body. This system is responsible for regulating various physiological responses, including heart rate, blood pressure, and smooth muscle contraction.
Adrenergic agents can be further divided into two main groups: adrenergic agonists and adrenergic antagonists. Adrenergic agonists stimulate the adrenergic receptors, leading to an increase in sympathetic nervous system activity. This can result in effects such as vasoconstriction, bronchodilation, and increased heart rate. Adrenergic agonists are commonly used in the treatment of conditions such as asthma, hypotension, and cardiac arrest.
On the other hand, adrenergic antagonists block the adrenergic receptors, thereby inhibiting the effects of sympathetic nervous system activation. These agents are often employed to lower blood pressure, treat certain heart conditions, and manage symptoms associated with conditions like benign prostatic hyperplasia. Adrenergic antagonists can be further classified into alpha-adrenergic antagonists and beta-adrenergic antagonists, based on their selectivity for different adrenergic receptor subtypes.
Pharmaceutical companies extensively utilize adrenergic agents as key components in the development of various medications. Adrenergic APIs offer targeted effects on the adrenergic system, allowing for precise modulation of physiological responses. The understanding of adrenergic agents and their mechanisms of action is vital for the design and optimization of drugs used in the treatment of numerous medical conditions. Researchers and scientists continue to explore and innovate within this subcategory to develop new adrenergic agents with enhanced efficacy and fewer side effects, ultimately improving patient outcomes.
Synephrine (Adrenergic agents), classified under Central Nervous System Agents
Central Nervous System (CNS) Agents are a crucial category of pharmaceutical Active Pharmaceutical Ingredients (APIs) that specifically target the central nervous system. The CNS encompasses the brain and spinal cord, playing a vital role in regulating and controlling various bodily functions, including cognition, movement, emotions, and sensory perception. These agents are designed to interact with specific receptors, enzymes, or ion channels within the CNS to modulate neural activity and restore normal functioning.
CNS agents comprise a diverse range of pharmaceutical APIs, including analgesics, anesthetics, antipsychotics, sedatives, hypnotics, anti-epileptics, and antidepressants. Each subcategory addresses distinct neurological disorders and conditions. For instance, analgesics alleviate pain by targeting receptors in the brain and spinal cord, while antipsychotics are employed to manage psychosis symptoms in mental illnesses such as schizophrenia.
The development of CNS agents involves rigorous research, molecular modeling, and extensive clinical trials to ensure safety, efficacy, and specific target engagement. Pharmaceutical companies invest significant resources in identifying novel drug targets, synthesizing new compounds, and optimizing their pharmacological properties. These agents undergo rigorous regulatory evaluations and must adhere to stringent quality standards and guidelines.
Given the prevalence of CNS disorders globally, the market demand for effective CNS agents is substantial. The development of innovative CNS APIs not only improves patient outcomes but also provides valuable commercial opportunities for pharmaceutical companies. Continued advancements in CNS agent research and development hold the promise of groundbreaking therapies that can improve the quality of life for individuals affected by neurological conditions.
